If a patient can realistically defer treatment, which is true in most cases based on liver disease stage,
patients might be better off waiting for new therapies, Chung said.
Patients with more advanced disease require treatment more urgently, whereas those with less advanced disease are able to wait.
While a BID dosing schedule is nice, the fundamental cooperative toxicity between interferon, ribavirin and a protease inhibitor must be factored into the mix, Chung added.